Laval – November 06, 2026 -- Only 62.0% of patients hospitalized with severe alcohol-associated hepatitis (AH) in the United States were estimated to survive 12 months, according to a real-world study from Bausch Health Companies Inc. and its gastroenterology unit, Salix Pharmaceuticals.
Study of 1,630 US adults tracks rehospitalization and transplant rates
The companies are presenting the poster, "Clinical Burden and Outcomes in a Large Real-World Cohort of Patients Hospitalized with Severe Alcohol-Associated Hepatitis," at the American Association for the Study of Liver Diseases' The Liver Meeting 2026. The meeting runs November 5-9 in Denver, Colorado. The cohort comprised 1,630 adults.
Rehospitalization climbs from 31.4% at 30 days to 69.1% at 12 months
Within 30 days of discharge, 31.4% of patients were rehospitalized. The estimated rate reached 69.1% by 12 months. The estimated liver transplantation rate at 12 months was 8.5%.
The data point to a heavy and recurring hospital burden for a patient group with limited transplant access. Bausch Health says the findings underscore the need for improved management strategies and effective therapies for severe AH.
Bausch Health's CMO calls for more real-world evidence
Jonathan Sadeh, M.D., M.Sc., Executive Vice President, Chief Medical Officer and Head of R&D at Bausch Health, described an "urgent unmet need" among patients hospitalized with severe AH. He said real-world evidence is essential to understanding patient needs and informing research priorities.
The poster, number 3154, was authored by Jesudian A, Voegel A, Gagnon-Sanschagrin P, et al.